Who makes selective alpha 1-blockers?

selective alpha 1-blockers is developed by Samsung Medical Center.

What development phase is selective alpha 1-blockers in?

selective alpha 1-blockers is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

selective alpha 1-blockers

Samsung Medical Center · FDA-approved active Small molecule Quality 2/100

The selective alpha 1-blockers, marketed by Samsung Medical Center, hold a established position in their therapeutic class. A key strength is the protection of the drug's composition, secured until the key patent expiry in 2028. The primary risk lies in the lack of disclosed revenue data, which may affect investment and market valuation assessments.

At a glance

Generic name	selective alpha 1-blockers
Also known as	tamsulosin, alfuzosin, doxazosin, terazosin
Sponsor	Samsung Medical Center
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

selective alpha 1-blockers CI brief — competitive landscape report
selective alpha 1-blockers updates RSS · CI watch RSS
Samsung Medical Center portfolio CI